Citius Oncology, Inc. CTOR Proceeds from debt financing, net of issuance costs
Proceeds from debt financing, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s proceeds from debt financing, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s proceeds from debt financing, net of issuance costs?
- Citius Oncology, Inc. (CTOR) reported proceeds from debt financing, net of issuance costs of $589.7K in Q3 2024.
- What does proceeds from debt financing, net of issuance costs mean?
- Measures the net cash inflows received from the issuance of debt instruments after deducting direct costs associated with the financing transaction. This metric highlights the company's ability to access capital markets and the effective cost of raising debt. It is essential for assessing liquidity and leverage management.